btdiver Posted - 1 hour ago

$GALT Someone doesn’t realize they just got muted. F_ing A, what’s a guy got to do to be clear? I hate that I get lured into these circular conversations with pikers and liars. At the end of the day, it’s on me for responding. But damn, clowns to the left of me, jokers to the right… To all the sincere investors and GALT bulls, here’s to the next leg up.

trader_b1 Posted - 2 hours ago

$GALT U don't realize U just acknowledged the significance of my question. Remember, I'm simply asking whehter its best to buy NOW or LATER. The current trial failed the gold standard of ITT making it rather easy for the FDA to withhold approval pending more data. Heck, even GALT is telling shareholders that more trials are likely. After all, they included 2 quotes in their P/R that says "the results warrant further clinical development". More trials = time and money. It takes 18-36 months for 1 patient to complete a trial. Between design, planning, full recruitment & data analysis we won't have results for at least 3 years, 4.5 if they go to 36 months for stat sig. So other than helping you with the your recent losses, why buy NOW? At best price goes sideways for a while. Even U acknowledge this when you say "someone will recognize the value of the asset in the next year". So I repeat, why buy now & risk a major loss to dilution when the best case is sideways movement for a while?

ThomasLD Posted - 4 hours ago

$GALT $220 / share is impossible but one can dream 😆 haha.

Justfacfs Posted - 5 hours ago

$GALT Heavy buying last 5 days. Last 5 days only buying by big institutions.. according to webull this how the trades happened in the last 5 days..something big to be announced soon .. FDA conditional submission may be.. as the results from trial were positive

ThomasLD Posted - 5 hours ago

$GALT Watch for short squeeze is coming after the markets have been analyzing the 18 months data readout.

btdiver Posted - 6 hours ago

$GALT $GALT Mezz financing doesn’t necessarily imply dilution; can become an equity position or not. Even if it were dilutive, that could be years in the future or after substantial value is realized for current shareholders. Primarily it’s a loan with bells & whistles. Could easily come from a company that might be a future acquirer, in which case, who cares about the dilution! Having addressed that, what is your definition of “final pay day?” All investment is a question of opportunity costs. IMO, GALT owns & has just demonstrated efficacy for an asset worth in excess of $3+ Billion. Cost of the company today is ~ $72 million. Thats roughly 2.5 cents on the $. Someone will recognize the value of the asset in the next year (hopefully sooner). Any time I can invest 2.5 cents to get back even 25 cents, I’m probably going to make that trade. With biotech, you’re not going to have many opportunities to buy once the market recognizes the value; it’s often just gobbled up.

ThomasLD Posted - 6 hours ago

$GALT I have learned from good investors here that Richard U Joined the board in 2017 but was a long time investor prior to joining the board. His net worth is around 10 billion. He is usually one of the largest GOP donors. He was #2 this year but last year was #1. He is fearless with his $$$. He is committed to the company. So, I think he will continue to help the company here financially for LT! Watch for short squeeze 💯💯💯💯💯💯

Kilarck Posted - 6 hours ago

$GALT This is going to market the FDA isn’t going to let millions of people start coughing up blood and die because they need confirmation of a trial that has been repeated in the waning dosing arm and has a great safety profile. They produced clinical data in a deadly condition without any safety flags. This is an incredibly fragile patient population and no other drug is even close to producing this kind of clinical data in cirrhosis. The FDA looks at the risk benefit and totality of all scientific evidence. You don’t know anything here. Accelerated Approval approach is realistic given: 1. High unmet need in MASH cirrhosis. 2. Significant PP efficacy at 18 months. 3. Safety advantage over standard approaches. 4. Surrogate Markers FibroScan® confirms the belapectin’s antifibrotic and portal pressure-lowering actions. You think anyone is going to put more burden on the transplant system. The FDA approved Madrigal with a marginal improve t based on biopsy data. LMAO

BioRich Posted - 6 hours ago

@Bark63 makes sense. I bought some extra quick hit shares at .88. And then am flipping profits into $GUTS. Still hold shares in $GALT but couldn't pass up cashing in on a 60% bump on the shares I just bought. What's your pitch on the one you mentioned? Always looking for new opportunities.

trader_b1 Posted - 7 hours ago

$GALT Now we're making progress! 1) You are admitting that more cash will be needed and that trials of some sort are likely. That alone is an admission that any final pay day has been delayed. So again I ask, is it better to buy now or put your money in an area that is working, and then use the profits to buy even more later. 2) Your argument is that they will get cash via some other means than a dilution (even though they diluted in the past). Sure, a pharma could agree to pay for the trials, but that won't be a donation. They'll want something in return, e.g. ownership (=dilution, or outright b/o but at at a deep discount). You also mentioned mezz financing but that's just a "fancy" way to say debt + dilution. The only thing you mention that would absolutely avoid dilution is something you also said you fear -- DU taking the company private, presumably ripping shareholders off at a price well below actual value. But yeah, I guess that would solve the dilution problem.

ThomasLD Posted - 7 hours ago

$GALT $AUPH Have a wonderful weekend all!

Etielibe Posted - 7 hours ago

$GALT shorts interest at 13/12 grew to 8269000 more +30% than end november… I hope that some of them buy today 😂😂 come on Galt💪

D_Coral Posted - 7 hours ago

$GALT That’s what I like to see! Evil short sellers distraught after their ill-informed short trade:

Tjcmd Posted - 8 hours ago

$GALT 50% of cirrhosis cases due to NASH and 50% are alcohol related. Eventually will be studied in alcohol induced cirrhosis or simply used off label…either way a potential doubling of TAM

btdiver Posted - 8 hours ago

$GALT I don’t know what you want me to say. I understand how dilution works. I don’t think you understand why there may not be additional trials required that would require dilution. For example, a joint venture with another firm could mean cash in, no additional shares created. Or, DU and his resources finance the taking of the company private. Do you think a multibillionaire and a couple of his cronies couldn’t get mezzanine financing from a private equity firm for $200,000,000 when they already own 50% of the company? I don’t have time to do all your due diligence for you and explain all the ways this can play out.

D_Coral Posted - 8 hours ago

$GALT It is just the very early beginning of a sustained run up to correct back to where it should be, $10 or $20 by now with what we have:

OpenOutcrier Posted - 9 hours ago

RECAP 12/27 Chatter: $PANW - DoS flaw RECAP 12/27 +Pos Comments: $FANG + CFRA RECAP 12/27 -Neg Comments: $GALT - HC Wainwright Live Breaking trading news www.openoutcrier.com

trader_b1 Posted - 9 hours ago

$GALT We all know its a deadly disease with no drug. No druig includes belapectin because it now seems likely that another trial will be need it to flush out the hidden gems from the last trial....and they will need more cash for that trial.....and if they need more cash, you will be diluted. We also know about Uihlein and the warrants. Did you know that those warrants were given out around the time of the last dilution? So again, the question is when is the best time to enter -- now, or after a dilution but before the 5-7 years it will take for the next trial. If you buy before the dilution you are literally donating your shares to Uihlein and all the other investors who will buy in at the diluted price.

Nunyabid Posted - 9 hours ago

$GALT Gap fill next week

RonnieReagan Posted - 9 hours ago

$GALT

ThomasLD Posted - 10 hours ago

$GALT For whoever doesn’t understand TAM is? There are a total of 2-3M cirrhosis patients. Peak sale could hit $8.8b Number of shares outstanding for GALT as of December 2024 : 62,278,000. BO ~ 8.8b / 0.062278 ~ $141 a share! So, it is easy for BO > $50+++

ThomasLD Posted - 10 hours ago

$GALT IF after FDA APPROVAL and if in face the value of this drug is $8.8b, then BO ~ $8.8b / 0.062278 ( 62,278,000 outstanding shares) ~ $141 a share. So, to be conservative, it could be bought out for >>>>> 50++++

Compound808 Posted - 10 hours ago

$GALT got in today at 1.18 hoping for more activity after hours Monday rally? comments appreciated on ideas of where this could head?

All_just_a_game Posted - 11 hours ago

$GALT lol

Lectin_Pectin Posted - 11 hours ago

$GALT watch the shorts squirm in discomfort 😂 It's all just a game, except posting misleading statements like your life depends on it

ThomasLD Posted - 11 hours ago

$GALT Possible partnership or more during JPM week in January, 2025 since they all know a good value of the drug in LT!

SFBP Posted - 11 hours ago

$GALT At this point DU is free to tell all of his billionaire friends what he thinks about the data to date. A few billionaires with the right insight can move this stock a lot.

oguzt Posted - 11 hours ago

$GALT where is this bipolar? Dude, seek treatment or don't invest in something that you don't understand.

Kilarck Posted - 11 hours ago

$GALT The FDA doesn’t care about biomarkers. The FDA cares about clinical outcome and patient survival. Also we have only seen the Fibroscan result the best NIT for cirrhosis which confirmed the fibrosis stabilization. That’s why we see varices being prevented varices are directly correlated with survival. The FDA gave the guidance in MASH to Madrigal $MDGL confirm the data with clinical results. $GALT just did that which the FDA asked Madrigal to do. The highest cost burden is in cirrhosis and keeping patients from needing transplants. Only a small percentage of MASH patients become cirrhotic. Cirrhosis is not MASH. MASH causes cirrhosis and the market doesn’t seem to understand that. The secondary clinical outcomes to be presented are all tied to portal hypertension which is what drives varices. We can expect hits in many secondary endpoints this will reduce the statistical noise from ITT. also we can assume ITT applied worst case scenario to the statistical analysis. FDA APPROVED

juni2419 Posted - 11 hours ago

$GALT